Top Ten most popular articles on Pharmafile.com this week
April 20, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, EMA, GW Pharma, J&J, JJ, MHRA, Mylan, Novartis, Sanofi, Shire, Takeda, biotech, drugs, epipen, keytruda, pharma, pharmaceutical
It’s the end of another week and there’s really been one story that has dominated the headlines – Takeda’s potential …
Lilly and Incyte’s resubmission of arthritis drug data fails to assuage FDA concerns
April 20, 2018Medical Communications, Sales and Marketing Eli Lilly, FDA, Incyte, baricitinib, pharma, rheumatoid arthritis
Eli Lilly and Incyte are facing more complications in the US approval of their experimental rheumatoid arthritis (RA) drug baricitinib …
Prototype skin implant signals cancer by forming a visible mole
April 20, 2018Medical Communications Cancer, device, implant, medtech, pharma
Researchers working with Professor Martin Fussenegger at the Department of Biosystems Science and Engineering at ETH Zurich in Basel have …
FDA advisory committee sets GW Pharma up for approval
April 20, 2018Medical Communications, Sales and Marketing Epidiolex, GW Pharma, biotech, drugs, pharma, pharmaceutical
After the FDA advisory committee unanimously recommended GW Pharma’s Epidiolex for approval, the chances of it not receiving the nod …
Allergan out but Takeda sticks to guns on Shire
April 20, 2018Medical Communications, Sales and Marketing Allergan, Shire, Takeda, biotech, drugs, pharma, pharmaceutical
Allergan performed an odd about-turn after initially declaring its interest in pursuing a deal for Shire, before reneging on that …
The UK’s Royalties withholding tax consultation: Pushing extraterritorial boundaries
April 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Norton Rose Fulbright, feature, pharma, tax consultation
Norton Rose Fulbright’s Dominic Stuttaford, James Baillieu and Susie Brain discuss the implications regarding the recent reforms to cross-border royalties.The …
AZ’s Tagrisso gets FDA nod in first-line EGFR-mutated lung cancer
April 19, 2018Sales and Marketing AstraZeneca, Cancer, EGFR-TKIs, NSCLC, Tagrisso, lung cancer, pharma
AstraZeneca has announced that its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) has received approval from …
BenevolentAI financing round takes valuation to $2bn+
April 19, 2018Medical Communications BenevolentAI, biotech, drugs, pharma, pharmaceutical
BenevolentAI, a London based drug discovery biotech, has revealed that a $115 million financing round now sees the company valued …
Novartis snatches Amgen and BMS veteran for CMO and Drug Development Head
April 19, 2018Medical Communications Amgen, BMS, Bristol-Myers Squibb, Novartis, appointment, pharma
Dr John Tsai has been welcomed to the fold as Novartis’ new Head of Global Development and Chief Medical Officer, …
Merck KGaA finds consumer health buyer in P&G for €3.4bn
April 19, 2018Sales and Marketing Merck KGaA, P&G, Pfizer, biotech, drugs, pharma, pharmaceutical
Merck KGaA has successfully found a buyer for its healthcare unit, after Proctor & Gamble announced that it was prepared …
EMA initiates divorce process from the UK’s MHRA
April 19, 2018Medical Communications EMA, UK government, biotech, brexit, drugs, pharma, pharmaceutical
The first stage of separation for the EMA from the UK came with the decision to relocate its headquarters to …
Immunomedics’ whirlwind in the C-suite continues
April 18, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Immunomedics hasn’t had the most straight forward year, its $2 billion deal with Seattle Genetics was scuppered by activist investors, …
Frequency Therapeutics hires industry vet
April 18, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Frequency Therapeutics is a biotech with big ideas and it has made a big appointment to back up those ideas, …
BMS’ Opdivo+Yervoy combo secures FDA approval in kidney cancer
April 18, 2018Research and Development, Sales and Marketing BMS, Bristol Myers Swuibb, Cancer, FDA, Yervoy, carcinoma, opdivo, pharma
The FDA has announced its approval of a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), both products from Bristol Myers …
EpiPen shortage hits UK and Canada hard, but not US
April 18, 2018Research and Development, Sales and Marketing Mylan, Pfizer, biotech, drugs, epipen, pharma, pharmaceutical
Manufacturing issues at the single Pfizer plant that produces the EpiPen epinephrine injector has caused serious shortages in the UK …
Amgen and Novartis’ Aimovig shines in migraine at Phase 3
April 18, 2018Research and Development Aimovig, Amgen, Novartis, migraine, pharma
Amgen has lifted the curtain on complete Phase 3 data for its calcitonin gene-related peptide receptor (CGRP) inhibitor Aimovig (erenumab) in …
Sanofi CFO set to step down this year
April 18, 2018Medical Communications, Research and Development Sanofi, biotech, cfo, drugs, pharma, pharmaceutical
After a busy start to the year, with a number of acquisitions and a few divestments, Sanofi’s Chief Financial Officer, …
All indications point to approval for cannabis-based therapy
April 17, 2018Research and Development, Sales and Marketing FDA, GW Pharma, biotech, drugs, pharma, pharmaceutical
GW Pharma are inching step by step towards a likely approval with the FDA, after it received a strong recommendation …
Novartis to invest $100m in new malaria treatments
April 17, 2018Manufacturing and Production, Research and Development Novartis, WHO, malaria, pharma
Novartis has revealed it is to invest $100 million into the research and development of new treatments for malaria over …
FDA flip-flops on Alkermes’ drug application
April 17, 2018Manufacturing and Production, Sales and Marketing Alkermes, FDA, biotech, drugs, pharma, pharmaceutical
Two weeks ago, it looked like the hopes for Alkermes’ ALKS 5461 receiving approval would rely on returning to the …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
